In a bid to make Coronavirus vaccines more affordable and available in the Middle East, the UAE is rolling out locally-manufactured ‘Hayat-Vax’ immunizations in collaboration with China’s Sinopharm CNBG.
Sinopharm, a pioneer of Covid-19 vaccines since the last six months with supplies of over 100 million doses globally, announced a joint venture between with Abu Dhabi-based technology company Group 42 (G42) to manufacture vaccines in the country and in partnership with Ras Al Khaimah-based pharma firm Julphar, it’s expected to produce two million doses every month.
In December 2020, the UAE’s Ministry of Health and Prevention (MOHAP) registered Sinopharm and their vaccines proved an impressive 86% efficacy in its initial trials, while Sinopharm reports a 79.34% efficacy based on its interim results.
“When COVID-19 began to spread rampantly last year, the UAE and its leading technology company G42 explored the possibility of hosting the clinical trials of a COVID-19 vaccine in the country. Sinopharm has undertaken the mission of fighting this pandemic and thanks to the close collaboration with the UAE, Sinopharm’s vaccine has been now administered to millions of people in the country, the region, and the world in a fundamental step towards defeating this virus. We are proud to partner with G42 in this new Joint Venture that will play a vital role in combatting COVID-19 globally, making an indelible contribution to the health of our communities.”Liu Jingzhen, Chairman of Sinopharm
In addition to Sinopharm’s joint venture with G42 to manufacture Coronavirus vaccines in the UAE, they also plan to build a vaccine plant this year; KIZAD, touted to have an annual production capacity of 200 million doses across three filling lines and five automated packaging lines.
Photograph credit: WAM
“The launch of the vaccine manufacturing capabilities in the UAE is a momentous step in the fight against COVID-19. We are grateful to the shared vision of the UAE and China, their true partnership and collaboration to make this a reality. This initiative in the UAE is a strategic advancement to future proof the population health of our nations. Our JV is also actively looking to bring our capabilities to new markets around the world.”Peng Xiao, CEO of G42
Featured photograph credit: WAM